



## **Fiona Milner appointed Epichem General Manager**

**30 May 2022 – Perth, Australia:** PharmAust Limited (ASX: PAA & PAAO), a clinical-stage biotechnology company, is pleased to announce that experienced pharmaceutical executive Fiona Milner has joined Epichem, a wholly owned subsidiary of PharmAust, as its new General Manager commencing 29 June 2022.

Ms Milner has 25 years' experience working in multinational companies in the pharmaceutical industry.

Most recently she was the Regional Sales Manager for Novartis Pharmaceuticals and has held a number of roles in this organisation over the last 14 years. She received the International First Line Manager Award in 2011 and 2019 from Novartis' Global CEO in Basel, Switzerland (one of only 35 recognised across the globe). She was also nominated for the 'Telstra Business Woman of the Year' Award in 2010 and 2011.

Prior to this, Ms Milner was the State Manager at pharmaceutical company Sanofi Aventis, a role she held for 11 years. Notably during her tenure, she grew and led the WA State branch in 2007 to contribute a Business Unit Total of \$56.4M to national sales. She received the Sanofi State of the Nation award six times and was also awarded Manager of the Year.

Ms Milner is based in Perth and holds a Bachelor of Science (BSc) in Zoology and Physiology as well as Diploma of Education majoring in Science and Mathematics.

"I am excited to bring a dynamic and clear commitment to drive growth and performance for Epichem – leading through promoting diversity, harnessing change and embracing commercial opportunities."

PharmAust Executive Chairman Dr Roger Aston said "We are all delighted that Fi has decided to join Epichem. She has an outstanding record in driving performance and adding value and we are confident that she will be able to grow and diversify the Epichem business and take the business to the next level of increased revenues and profitability."

PharmAust is also pleased to advise that Epichem recently appointed a Business Development Manager, Ingrid Klopper.

Ms Klopper has a Bachelor of Science majoring in Chemistry and Applied Chemistry. She has studied both Computer Science and Information Systems at University and recently completed a Google certified course in Digital Marketing.

Ms Klopper has over 10 years' experience in technical sales and account management in B2B sales and business development. She has worked across a broad range of industries including life sciences, biotech, mining, industrial, agriculture, marine and construction.

She will support Epichem's strategy in business development, marketing, sales and social media to create and build long term business relationships and to identify new clients and new projects across all five divisions of the Epichem business.

**This announcement is authorised by the Board**

**Enquiries:**

**Dr Roger Aston**  
**Executive Chairman**  
**Tel: 0402 762 204**  
**[rogeraston@pharmaust.com](mailto:rogeraston@pharmaust.com)**

**P +61 (8) 9202 6814**  
**F +61 (8) 9467 6111**  
**W [www.pharmaust.com](http://www.pharmaust.com)**

**About PharmAust Limited:**

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated \$2.2 million in sales of goods & services in FY 2021

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.

**About Epichem:**

Epichem is a wholly owned subsidiary of the ASX listed company PharmAust Limited. Located in Technology Park, Western Australia, Epichem has been delivering products and services in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries in over 40 countries worldwide for over 18 years.

Epichem has newly constructed purpose-built, state-of-the-art laboratories and has world class equipment and expertise in synthetic and medicinal chemistry to support drug discovery projects, and for the cost-effective synthesis of drug analogue libraries and intermediates. It also has a rapidly growing catalogue of pharmaceutical reference standards.

Epichem also specialises in Custom Synthesis, Analytical Chemistry and Materials Science. Epichem is the winner of the WA Industry Export Award 2021 for International Health, an award also won in 2019, 2018 and 2017, the 2020 Inspiring Story of Celebrating Remarkable Resilience Nomination for WA for the Australian Export and Investment Awards and the 2021 and 2020 GHP Biotechnology Award winner for Most Innovative Chemistry Service Provider –Australia and Best in Organic Chemistry Solutions. Epichem has been inducted into the WA Export Hall of Fame.

For more information, visit [www.epichem.com.au](http://www.epichem.com.au)